Clinical trial NCT04995419: A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
Official title: A Single-arm, Open-label, Multi-center Phase 2 Study of Enfortumab Vedotin (ASG-22CE) in Chinese Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and PD 1/PD-L1 Inhibitor Therapy (EV-203)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Metastatic Urothelial Cancer
Keywords: Enfortumab Vedotin
PADCEV
ASG-22CE
Pharmacokinetics
Urothelial cancer
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Seagen Inc.
First posted: 2021-08-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to determine the antitumor activity of enfortumab vedotin (EV) confirmed by the objective response rate (ORR).

This study also evaluated the effect of antibody-drug conjugate (ADC), total antibody (TAb) and monomethyl auristatin E (MMAE) in Chinese participants with locally advanced or metastatic urothelial cancer.

In addition, the study also evaluated the duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immunogenicity determined by the incidence of antitherapeutic antibodies (ATA).

Safety and tolerability of EV in participants with locally advanced or metastatic urothelial cancer was also evaluated.

Detailed description: This study comprised of a single group of participants who received one dose of enfortumab vedotin (EV) on Days 1, 8 and 15 of every 4-week (28 days) cycle. Participants continued on study treatment until discontinuation.

After treatment discontinuation, participant had an end of treatment (EOT) visit for a 30-day Safety Follow-up.

Participants to discontinue to treatment for reasons other than disease progression were followed for response assessments.

A Pharmacokinetic (PK) cohort was available at some study centers. Participants enrolled at the PK cohort site(s) had intense PK samples collected after single and repeated doses.

Eligibility criteria: Inclusion Criteria:

* Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Participant must have histologically or cytologically documented urothelial/transitional cell carcinoma of the bladder, renal pelvis, ureter or urethra. Other histologies including adenocarcinoma, squamous differentiation or mixed are eligible.
* Participant has locally advanced or metastatic disease that is not amenable to curative intent treatment. Participants must have measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors (RECIST) ( Version 1.1). Lesions in a prior radiation field must have progressed subsequent to radiotherapy to be considered measurable.
* Participant must have received prior treatment with PD-1/PD-L1 inhibitor therapy in the locally advanced or metastatic urothelial cancer setting. Participants who received PD-1/PD-L1 therapy in the neoadjuvant/adjuvant setting and had recurrent or progressive disease either during therapy or within 3 months of therapy completion are eligible.
* Participant who received prior treatment with platinum-containing chemotherapy defined as those who received platinum in the neoadjuvant/adjuvant setting and had recurrent or progressive disease within 12 months of completion or received treatment with platinum in the locally advanced (defined as unresectable with curative intent) or metastatic setting.

  * Platinum based chemotherapy may include combination use with a PD-1 or PD-L1 inhibitor.
* Participant has the following baseline laboratory data. If a participant has received a recent blood transfusion or growth factor, the hematology tests must be obtained ≥7 days after any growth factor and ≥ 28 days after any blood transfusion.

  * absolute neutrophil count (ANC) ≥ 1.0 × 10\^9/L
  * platelet count ≥ 100 × 10\^9/L
  * hemoglobin ≥ 9 g/dL
  * serum total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for participants with Gilbert's disease
  * creatinine clearance (CrCl) ≥ 30 mL/min as estimated per institutional standards or as measured by 24-hour urine collection (glomerular filtration rate \[GFR\] can also be used instead of CrCl).
  * alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
* Female participant is not pregnant and at least one of the following conditions apply:

  * Not a woman of childbearing potential (WOCBP)
  * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after the last dose of study treatment administration.
* Female participant must agree not to breastfeed starting at screening and throughout the study period and for at least 6 months after the last dose of study treatment administration.
* Female participant must not donate ova starting at first dose of study treatment and throughout the study period and for 6 months after the last dose of study treatment administration.
* Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 6 months after the last dose of study treatment administration.
* Male participant must not donate sperm during the treatment period and for 6 months after the last dose of study treatment administration.
* Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 6 months after the last dose of study treatment administration.
* Participant agrees not to participate in another interventional study while receiving study treatment in the present study.
* Participant must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.
* Participant must have an anticipated life expectancy of ≥ 3 months.

Exclusion Criteria:

* Participant has preexisting sensory or motor neuropathy Grade ≥ 2.
* Participant has active central nervous system (CNS) metastases. Participants with treated CNS metastases are permitted on study if all the following are true:

  * CNS metastases have been clinically stable for ≥ 6 weeks prior to screening.
  * If requiring steroid treatment for CNS metastases, the participant is on a stable dose ≤ 20 mg/day of prednisone or equivalent for ≥ 2 weeks.
  * Baseline imaging scans show no evidence of new or enlarged brain metastasis.
  * Participant does not have leptomeningeal disease.
* Participant has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).
* Participant with ongoing ≥ Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism is excluded. Participant with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or participants with other immunotherapy-related AEs requiring high doses of steroids (\> 20 mg/day of prednisone or equivalent), is excluded. Participant with ≤ Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well-maintained/controlled on a stable dose of hormone replacement therapy (if indicated).
* Participant has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥ 8 percent or HbA1c between 7 percent and \< 8 percent with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.
* Participant has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADCs).
* Participant has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Participants with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
* Participant is currently receiving systemic antimicrobial treatment for viral, bacterial or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.
* Participants with a positive hepatitis B surface antigen and/or anti-hepatitis B core antibody and a negative polymerase chain reaction (PCR) assay at baseline should receive appropriate antiviral prophylaxis or regular surveillance monitoring as per local or institutional guidelines.
* Active hepatitis C infection or known human immunodeficiency virus (HIV) infection. Participant who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of ≥ 12 weeks.
* Participant has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.
* Participant had major surgery within 2 weeks or radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug. Toxicities from these therapies must have resolved or adequately stabilized before starting study treatment.
* Participant has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) or participant has known hypersensitivity to biopharmaceuticals produced in CHO cells.
* Participant has known active keratitis or corneal ulcerations. Participant with superficial punctate keratitis is allowed if the disorder is being adequately treated.
* Participant has any condition which makes the participant unsuitable for study participation.
* Uncontrolled tumor-related bone pain or impending spinal cord compression. Participant requiring pain medication must be on a stable regimen for at least 2 weeks at the time of first dose.

Primary outcomes:
measure: Objective Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors V1.1 (RECIST V1.1)
timeFrame: From first dose up to progressive disease or death (maximum duration: 9.33 months)
measure: Pharmacokinetics (PK) of Antibody-Drug Conjugate (ADC), Total Antibody (TAb), in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of Monomethyl Auristatin E (MMAE) in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of MMAE in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC , TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1: pre-dose
measure: PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1: pre-dose
measure: PK of ADC, TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose
measure: PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose
measure: PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1 : pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1
timeFrame: Cycle 1 Day 1 : pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Plasma: Accumulation Ratio of Cmax (RacCmax)
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Accumulation Ratio of AUC0-7d ( RacAUC0-7d)
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Terminal Elimination Half-life (t1/2)
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Systemic Clearance (CL)
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
measure: PK of ADC, TAb, MMAE in Serum: Volume of Distribution at Steady State (Vss)
timeFrame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Secondary outcomes:
measure: Duration of Response (DOR) as Per RECIST V1.1 Per IRC
timeFrame: From date of the first CR/PR up to progressive disease or death (maximum duration: 9.33 months)
measure: Duration of Response (DOR) as Per RECIST V1.1 Per Investigator's Assessment
timeFrame: From date of the first CR/PR up to progressive disease or death (maximum duration: 9.33 months)
measure: Objective Response Rate (ORR) as Per Investigator Assessment
timeFrame: From first dose up to progressive disease or death (maximum duration: 9.33 months)
measure: Disease Control Rate (DCR) as Per RECIST V1.1 Per IRC
timeFrame: From first dose up to progressive disease or death (maximum duration: 9.33 months)
measure: Disease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's Assesment
timeFrame: From first dose up to progressive disease or death (maximum duration: 9.33 months)
measure: Progression Free-Survival Per RECIST V1.1 Per IRC
timeFrame: From first dose up to progressive disease or death (maximum duration: 9.33 months)
measure: Progression Free-Survival Per RECIST V1.1 Per Investigator's Assessment
timeFrame: From first dose up to progressive disease or death (maximum duration: 9.33 months)
measure: Overall Survival (OS)
timeFrame: From first dose up to death (maximum duration: 9.33 months)
measure: Number of Participants With Antitherapeutic Antibodies (ATA)
timeFrame: From first dose until 9.33 months
measure: Number of Participants With Treatment Emergent Adverse Events
timeFrame: Baseline up to 9.33 months
measure: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
timeFrame: End of Treatment (Baseline up to 9.33 months)
Other outcomes:
Locations:
city: Beijing
country: China
facility: Site CN86001
city: Changsha
country: China
facility: Site CN86009
city: Guangzhou
country: China
facility: Site CN86002
city: Hangzhou
country: China
facility: Site CN86006
city: Nanjing
country: China
facility: Site CN86007
city: Shanghai
country: China
facility: Site CN86004
city: Wuhan
country: China
facility: Site CN86003
Study officials:
affiliation: Astellas Pharma China, Inc.
name: Senior Medical Science Manager
role: STUDY_DIRECTOR
References: